Panitumumab
Based on 2 publication(s) in Google Scholar
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer.
For research use only. We do not sell to patients.
- Purity: 99.77%
- CAS No.: 339177-26-3
- Molecular Weight:144.32 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Panitumumab
More-
WB
-
IF
All EGFR Isoforms
More
Biological Activity
Human IgG2 kappa
Human
EGFR
Panitumumab (2 nM-2 μM, 3 h) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells[3].
Panitumumab (0-200 μg/mL, 48 h) inhibits the proliferation of DLD-1 cells[4].
Panitumumab (80 μg/mL, 24 h) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells
-
Concentration:2, 20, 200, 2000 nM
-
Incubation Time:3 h
-
Result:Inhibited ligand-induced autophosphorylation of EGFR.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCI-H1975 and NCI-H1650 xenografts[3]
-
Dosage:25, 100, or 500 μg/mouse
-
Administration:Intraperitoneal injection (i.p.), twice a week
-
Result:Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.
Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.
P00533-1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 339177-26-3
-
Appearance Liquid
-
Molecular Weight 144.32 kDa
-
Color Colorless to light yellow
-
SMILES
[Panitumumab]
-
Synonyms
ABX-EGF
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis. [Abstract]2022 Jul 7;12(1):11561. PMID: 35798841
Panitumumab purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Jul 7;12(1):11561. [Abstract]
HeLa cells were pretreated with 100 nM cetuximab (Cmab) or 30 nM panitumumab (Pmab) for 10 min and then stimulated with 20 ng/mL TNF-α for 15 or 60 min. The expression of the indicated proteins was detected by immunoblotting.
Panitumumab purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Jul 7;12(1):11561. [Abstract]
Panitumumab (100 nM, 25 min) was internalized upon stimulation with TNF-α (20 ng/mL, 15 min) in HeLa cells.
-
Electrophoresis
A Separation Buffers Platform Set to Facilitate CZE Charge Heterogeneity Method Development for Monoclonal Antibodies. [Abstract]2026 Mar 24. PMID: 41873887
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Giannopoulou E, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82. PMID: 20044619.. . . [Content Brief]
[2]. Yu Jo Chua, et al. Panitumumab. Drugs Today (Barc). 2006 Nov;42(11):711-9. [Content Brief]
[3]. Stefan Stremitzer, et al. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014 Jun;13(6):843-51. [Content Brief]
[4]. Daniel J. Freeman, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther (2009) 8 (6): 1536–1546. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)